Astellas

News

EU clears review of Xtandi in earlier-stage prostate cancer

The EMA will kick off a review of Astellas and Pfizer's prostate cancer therapy Xtandi in an earlier-stage form of the cancer, which if approved could give the product a l

News

Astellas adds to cell therapy drive with Poseida deal

Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.

News

Astellas' Iveric takeover rewarded with FDA nod for GA drug

The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company

Oncology

Suffering beyond physical effects: inequalities and taboos i...

In this episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with André Deschamps, formerly president of Europa Uomo, the voice of men with prostate cancer in Europe.

News

Astellas builds in protein degraders with PeptiDream deal

Astellas has made another move into the area of protein degrader drugs, announcing its second partnership in the category in the space of two months.

News

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a

EU clears review of Xtandi in earlier-stage prostate cancer

Astellas adds to cell therapy drive with Poseida deal

Astellas' Iveric takeover rewarded with FDA nod for GA drug

Suffering beyond physical effects: inequalities and taboos i...

Astellas builds in protein degraders with PeptiDream deal

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Astellas

Editor's Picks